Management Of Systemic Lupus ... Health Article

References

1 DJ Wallace Principles of therapy and local measures Wallace DJ Hahn BH Dubois' Lupus Erythematosus 6th ed. 2002 Lippincott Williams & Wilkins Philadelphia 1131
2 KA Kirou DT Boumpas Systemic glucocorticoid therapy in systemic lupus erythematosus Wallace DJ Hahn BH Dubois' Lupus Erythematosus 6th ed. 2002 Lippincott Williams & Wilkins Philadelphia 1173
3 WW Chatham RP Kimberly Treatment of lupus with corticosteroids Lupus 10 3 2001 140 147
4 M Ostensen PM Villiger Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus Lupus 10 3 2001 135 139
5 RA Bonnel ML Villalba CB Karwoski J Beitz Aseptic meningitis associated with rofecoxib Arch Intern Med 162 6 2002 713 715
6 MJ Langman DM Jensen DJ Watson Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs JAMA 282 1999 1929
7 CJ Hawkey Progress in prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions: Omeprazole NSAID Steering Committee Am J Med 104 3A 1998 67S
8 DJ Wallace Antimalarial therapies Wallace DJ Hahn BH Dubois' Lupus Erythematosus 6th ed. 2002 Williams & Wilkins Philadelphia, Lippincott 1149
9 Canadian Hydroxychloroquine Study Group A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus N Engl J Med 324 1991 150
10 RF van Vollenhoven LM Morabito EG Engleman Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months J Rheumatol 25 1998 285
11 MA Petri RG Lahita RF Van Vollenhoven Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: A double-blind, randomized, placebo-controlled trial Arthritis Rheum 46 7 2002 1820 1829
12 EI Sato Methotrexate therapy in systemic lupus erythematosus Lupus 10 3 2001 162 164
13 CF Remer MH Weisman DJ Wallace Benefits of leflunomide in systemic lupus erythematosus: A pilot observational study Lupus 10 7 2001 480 483
14 AJ Wysenbeek DA Block JF Fries Prevalence and expression of photosensitivity in systemic lupus erythematosus Ann Rheum Dis 48 1989 461
15 WW Ting RD Sontheimer Local therapy for cutaneous and systemic lupus erythematosus: Practical and theoretical considerations Lupus 10 3 2001 171 184
16 JP Callen Management of skin disease in patients with lupus erythematosus Best Pract Res Clin Rheumatol 16 2 2002 245 264
16a SL Walker B Kinby RJ Chalmers The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus Br J Dermatol 147 2002 405 406
17 GF Duna JM Cash Treatment of refractory cutaneous lupus erythematosus Rheum Dis Clin North Am 21 1995 99
18 A Al-Herz M Schulzer JM Esdaile Survey of antimalarial use in lupus pregnancy and lactation J Rheumatol 29 4 2002 700 706
19 DT Boumpas BJ Fessler HA Austin III Systemic lupus erythematosus: Emerging concepts. II. Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis Ann Intern Med 123 1995 42
20 KF Thomson MJ Goodfield Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus J Dermatolog Treat 12 3 2001 145 147
21 MY Karim G Ruiz-Irastorza MA Khamashta GR Hughes Update on therapy: Thalidomide in the treatment of lupus Lupus 10 3 2001 188 192
22 T Toshimasu T Ohtani T Sakamato Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematousus and dermatomyositis Eur J Dermatol 12 2002 50 52
23 PS McKinley SC Ouellette GH Winkel The contributions of disease activity, sleep patterns and depression to fatigue in systemic lupus erythematosus: A proposed model Arthritis Rheum 38 1995 826
24 B Wang DD Gladmann MB Urowitz Fatigue in lupus is not correlated with disease activity J Rheumatol 25 1998 892
25 VE Pollak CL Pirani RM Kark Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis J Lab Clin Med 57 1961 495
26 VE Pollak AK Dosekun Evaluation of treatment in lupus nephritis: Effects of prednisone Am J Kidney Dis 2 Suppl 2 1982 170
27 ES Cathcart MA Scheinberg BA Idelson Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis Lancet 1 1976 163
28 DA Isenberg WJW Morrow ML Snaith Methylprednisolone pulse therapy in the treatment of systemic lupus erythematosus Ann Rheum Dis 41 1982 347
29 KS Barron DA Person EJ Brewer Jr Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis J Pediatr 101 1982 137
30 MR Liebling K McLaughlin S Boonsue Monthly pulses of methylprednisolone in SLE nephritis J Rheumatol 9 1982 543
31 DR Boumpas HA Austin III EM Vaughn Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis Lancet 340 1992 741
32 R Sesso M Monteiro E Sato A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis Lupus 3 1994 107
33 MF Gourley HA Austin III D Scott Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis Ann Intern Med 125 1996 549
34 GG Illei HA Austin M Crane Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome wtihout adding toxicity in patients with lupus nephritis Ann Intern Med 135 2001 248 257
35 GL Ackerman Alternate-day steroid therapy in lupus nephritis Ann Intern Med 72 1970 511
36 AS Fauci Alternate day corticosteroid therapy Am J Med 64 1978 729
37 EL Dubois Nitrogen mustard in treatment of systemic lupus erythematosus Arch Intern Med 93 1954 667
38 BH Hahn OS Kantor CK Osterland Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: Report of a prospective controlled trial in 24 patients Ann Intern Med 85 1975 597
39 VK Bansal JA Beto Treatment of lupus nephritis: A meta-analysis of clinical trials Am J Kidney Dis 29 1997 193
40 JE Balow HA Austin III GC Tsokos Lupus nephritis Ann Intern Med 106 1987 79
41 EM Ginzler AJ Bollet EA Friedman The natural history and response to therapy of lupus nephritis Annu Rev Med 31 1980 463
42 DB Hellmann M Petri Q Whiting O'Keefe Fatal infections in systemic lupus erythematosus: The role of opportunistic organisms Medicine 66 1987 341
43 JH Klippel Systemic lupus erythematosus: Treatment related complications superimposed on chronic disease JAMA 263 1990 1812
44 JV Donadio Jr RJ Glassock Immunosuppressive drug therapy in lupus nephritis [Review] Am J Kidney Dis 21 1993 239
45 EJ Lewis The treatment of lupus nephritis: Revisiting Galen Ann Intern Med 21 2001 296 298
46 L Fraenkel S Bogardus J Concato Patient preferences for treatment of lupus nephritis Arthritis Rheum 47 2002 421 428
47 GG Illei K Takada D Psarkin Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term follow-up of a cohort of 145 patients participating in randomized controlled studies Arthritis Rheum 46 2002 995 1002
48 AD Steinberg SC Steinberg Longterm preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only Arthritis Rheum 34 1991 945
49 E Ciruelo J de la Cruz I Lopez Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide Arthritis Rheum 39 1996 2028
50 DT Boumpas HA Austin III EM Vaughan Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy Ann Intern Med 119 1993 366
51 BD Pryor SG Bologna LE Kahl Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus Arthritis Rheum 39 1996 1475
52 B Hellmich A Schnabel WL Gross Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor Semin Arthritis Rheum 29 1999 82 99
53 FA Houssiau C Vasconcelos D D'Cruz Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide Arthritis Rheum 46 2002 2121 2131
54 CC Mok CT Ho KW Chan Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine Arthritis Rheum 46 2002 1003 1013
55 TM Chan FK Li CS Tang Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhous Nephrology Study Group N Engl J Med 343 2000 1156 1162
55a EM Ginzler C Aranow JT Merrill Toxicity and tolerability of mycophenolate mofetil vs. intravenous cyclophosphamide in a multicenter trial as induction therapy for lupus nephritis [Abstract] Arthritis Rheum 48 2003 S586
55b EM Ginzler C Aranow J Buyon A multicenter study of mycophenolate mofetil vs. intravenous cyclophosphamide as induction therapy for severe lupus nephritis: Preliminary results [Abstract] Arthritis Rheum 48 2003 S647
56 ER Eiser HM Shanies Treatment of lupus interstitial lung disease with intravenous cyclophosphamide Arthritis Rheum 37 1994 428
57 DT Boumpas S Barez JH Klippel Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus Ann Intern Med 112 1990 674
58 CR deVries FS Freiha Hemorrhagic cystitis: A review J Urol 143 1990 1
59 BA Walz LeBlanc P Dagenais MB Urowitz Methotrexate in systemic lupus erythematosus J Rheumatol 21 1994 836
60 JR Carneiro EI Sato Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus J Rheumatol 26 6 1999 1275 1279
61 EI Sato Methotrexate therapy in systemic lupus erythematosus Lupus 10 2001 162 164
62 RW McMurray KB Elbourne A Lagoo Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB/NZW F1 mouse model of systemic lupus erythematosus J Rheumatol 25 1998 2364
63 TM Chan WS Wong CS Lau Prolonged followup of patients with diffuse proliferative lupus nephritis treated with prednisone and mycophenolate mofetil [Abstract] J Am Soc Nephrol 12 2001 195A
64 MY Karim P Alba MJ Cuadrado Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents Rheumatology 41 2002 876 882
65 Roche Laboratories: Cellcept (mycophenolate mofetil capsules) Physician's Desk Reference 52nd ed. 1998 Medical Economics New Jersey, Montvale 2265
66 MA Dooley S Hogan C Jennette Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans Kidney Int 51 1997 1188 1195
67 JP Lea Lupus nephritis in African Americans Am J Med Sci 323 2002 85 89
68 LW Fu LY Yang WP Chen Clinical efficacy of cyclosporin as neoral in the treatment of paediatric lupus nephritis with heavy proteinuria Br J Rheumatol 37 1998 217
69 F Dammacco O Della Casa Alberighi G Ferraccioli Cyclosporine-A plus steroid versus steroids alone in the 12-month treatment of systemic lupus erythematosus Int J Clin Lab Res 30 2000 67 73
70 SJ Morton RJ Powell An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: Limitations of its use Ann Rheum Dis 59 2000 487 489
71 D Caccavo B Lagana AP Mitterhofer Long-term treatment of systemic lupus erythematosus with cyclosporin A Arthritis Rheum 40 1997 27
72 CF Remer MH Weisman DJ Wallace Benefits of leflunomide in systemic lupus erythematosus: A pilot observational study Lupus 10 2001 480 483
73 AE Traynor J Schroeder RM Rosa Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: A phase I study Lancet 356 2000 701 707
74 DE Furst Stem cell transplantation for autoimmune disease: progress and problems Curr Opin Rheumatol 14 2002 220 224
75 A Tyndall J Passweg A Gratwohl Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases Ann Rheum Dis 60 2001 702 707
75a AE Trayner WG Barr RM Rosa Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after 5 years and 15 patients Arthritis Rheum 46 2002 2917 2923
76 RA Brodsky M Petri BD Smith Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease Ann Intern Med 129 1998 1031
77 BH Hahn Antibodies to DNA N Engl J Med 338 1998 1359
78 EJ terBorg G Horst EJ Hummel Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: A long-term, prospective study Arthritis Rheum 33 1990 634
79 JM Esdaile M Abrahamowicz L Joseph Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: Why some tests fail Arthritis Rheum 39 1996 370
80 DD Gladman MB Urowitz EC Keystone Serologically active clinically quiescent systemic lupus erythematosus: A discordance between clinical and serologic features Am J Med 66 1979 210
81 H Bootsma P Spronk R Derksen Prevention of relapses in systemic lupus erythematosus Lancet 345 1995 1595
82 DF Battafarano NJ Battafarano L Larsen Antigen-specific antibody responses in lupus patients following immunization Arthritis Rheum 41 1998 1828
83 Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis American College of Rheumatology Task Force on Osteoporosis Guidelines Arthritis Rheum 39 1996 1791
84 G Cunnane NE Lane Steroid-induced osteoporosis in systemic lupus erythematosus Rheum Dis Clin North Am 26 2 2000 311 329
85 A Zonana-Nacach SG Barr LS Magder M Petri Damage in systemic lupus erythematosus and its association with corticosteroids Arthritis Rheum 43 8 2000 1801 1808
86 R Ramsey-Goldman S Manzi Association of osteoporosis and cardiovascular disease in women with systemic lupus erythematosus Arthritis Rheum 44 10 2001 2338 2341
87 J Sanchez-Guerrero MH Liang EW Karlson Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus Ann Intern Med 122 1995 430
88 J Sanchez-Guerrero EW Karlson MH Liang Past use of oral contraceptives and the risk of developing systemic lupus erythematosus Arthritis Rheum 40 1997 804
88a Buyon JP, Petri M, Kim M et al: Estrogen/cyclic progesterone replacement is associated with an increased rate of mild/moderate but not severe flares in SLE patients in the SELENA trial. Presented at ACR as late-breaking abstract, 2003. http://www.abstractsonline.com
89 Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy post-menopausal women: Principal results from the Women's Health Initiative randomized controlled trial JAMA 17 2002 321 323
90 S Manzi F Selzer K Sutton-Tyrrell Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus Arthritis Rheum 42 1 1999 51 60
91 S Manzi EN Meilahn JE Rairie Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study Am J Epidemiol 145 1997 408 415
91a MJ Roman BA Shanker A Davis Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus N Eng J Med 349 2003 2399 2406
91b Y Asanuma A Oeser AK Shintani Premature coronary artery atherosclerosis in SLE N Eng J Med 349 2003 2407 2415
92 M Petri Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort Lupus 9 3 2000 170 175
93 HG Schrott RS Blumenthal R Levy HERS Study Group: Statin therapy, cardiovascular events, and total mortality in the heath and Estrogen/Progestin Replacement Study (HERS) Circulation 105 2002 2962 2967
94 AS Wierzbicki Lipid-lowering drugs in lupus: An unexplored therapeutic intervention Lupus 10 3 2001 233 236
95 M Petri Clinical and management aspects of the antiphospholipid syndrome Wallace DJ Hahn BH Dubois' Lupus Erythematosus 6th ed. 2002 Williams & Wilkins Baltimore, Lippincott 1093
96 MA Khamashta MJ Cuadrado F Mujic The management of thrombosis in the antiphospholipid-antibody syndrome N Engl J Med 332 1995 993
97 MH Rosove PMC Brewer Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients Ann Intern Med 117 1992 303
98 G Ruiz-Irastorza MA Khamashta BJ Hunt Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: Analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5 Arch Intern Med 162 2002 1164 1169
99 PV Rocca LB Siegel TR Cupps The concomitant expression of vasculitis and coagulopathy: Synergy for marked tissue ischemia J Rheumatol 21 1994 556
100 RC Kitridou The mother in systemic lupus erythematosus. The fetus in systemic lupus erythematosus Wallace DJ Hahn BH Dubois' Lupus Erythematosus 6th ed. 2002 Williams & Wilkins Baltimore, Lippincott 985 1023
101 LE Moore JN Martin Jr When betamethasone and dexamethasone are unavailable: Hydrocortisone J Perinatol 21 7 2001 456 458
102 TM O'Shea LW Doyle Perinatal glucocorticoid therapy and neurodevelopmental outcome: An epidemiologic perspective Semin Neonatol 6 4 2001 293 307
103 M Empson M Lassere JC Craig JR Scott Recurrent pregnancy loss with antiphospholipid antibody: A systematic review of therapeutic trials Obstet Gynecol 99 1 2002 135 144
104 R Rai H Cohen M Dave Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies Br Med J 25 1997 314
105 CA Laskin C Bombardier ME Hannah Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss N Engl J Med 337 1997 148
106 FS Cowchock EA Reece D Balaban Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatment Am J Obstet Gynecol 166 1992 1318
107 MD Lockshin ML Druzin MA Qamar Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody Am J Obstet Gynecol 169 1989 439
108 RG Farquharson S Quenby M Greaves Antiphospholipid syndrome in pregnancy: A randomized, controlled trial of treatment Obstet Gynecol 100 3 2002 408 413
109 LA Lee Neonatal lupus: Clinical features, therapy, and pathogenesis Curr Rheumatol Rep 3 5 2001 391 395
110 CE Tseng JP Buyon Neonatal lupus syndromes Rheum Dis Clin North Am 23 1997 31
111 JP Moak KS Barron TJ Hougen Congenital heart block: development of late-onset cardiomyopathy, a previously under-appreciated sequela J Am Coll Cardiol 37 1 2001 238 242
112 S Saleeb J Copel D Friedman JP Buyon Comparison of treatment with fluorinated glucocorticoids to the natural history of autantibody-associated congenital heart block: Retrospective review of the research registry for neonatal lupus Arthritis Rheum 42 1999 2335 2345
113 P Jacobs L Wood The comparison of gamma globulin to steroids in treating adult immune thrombocytopenia: An interim analysis Blut 59 1989 92
114 C Arnal JC Piette J Leone Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases J Rheumatol 29 1 2002 75 83
115 AJ Hakim SJ Machin DA Isenberg Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: The response to splenectomy Semin Arthritis Rheum 28 1998 20
116 S Hall JL McCormick Jr PR Greipp Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus Ann Intern Med 102 1985 325
117 SG West SC Johnson Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus Ann Intern Med 108 1988 703
118 R Blanco VM Martinez-Taboada V Rodriguez-Valverde Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases Br J Rheumatol 36 1997 1095
119 BJ Weill CJ Menkes C Cormier Hepatocellular carcinoma after danazol therapy J Rheumatol 15 1988 1447
120 B Hellmich A Schnabel WL Gross Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor Semin Arthritis Rheum 29 2 1999 82 99
121 RK Burt A Fassas J Snowden Collection of hematopoietic stem cells from patients with autoimmune diseases Bone Marrow Transplant 28 1 2001 1 12
122 D Hermosillo-Romo RL Brey Neuropsychiatric involvement in systemic lupus erythematosus Curr Rheumatol Rep 4 4 2002 337 344
123 ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes Arthritis Rheum 42 1999 599 For definitions, see Internet site www.rheumatology.org , click on Arthritis Rheum, click on Appendix A: Case definitions for neuropsychiatric syndromes in SLE.
124 SD Denburg RM Carbotte JA Denburg Corticosteroids and neuropsychological functioning in patients with SLE Arthritis Rheum 37 1994 1311
125 SL Kolasinski JB Chung DA Albert What do we know about lupus membranous nephropathy? An analytic review Arthritis Rheum 47 4 2002 450 455
126 HA Austin III DT Boumpas EM Vaughan Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data Kidney Int 45 1994 544
127 F Musio EM Bohen CM Yuan Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus Semin Arthritis Rheum 28 1998 1
128 HH Eular JO Schroeder P Harten Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide Arthritis Rheum 37 1994 1784
129 DJ Lewis LG Hunsicker SP Lan Lupus Nephritis Collaborative Study Group A controlled trial of plasmapheresis therapy in severe lupus nephritis N Engl J Med 326 1992 1373
130 D Wofsy WE Seaman Reversal of advanced murine lupus in NZB/NZW F1 mice by in vivo treatment with anti-L3T4 J Immunol 138 1987 2089
131 BH Hahn FM Ebling Suppression of murine lupus nephritis by administration of an antiidiotypic antibody to antiDNA J Immunol 132 1984 187
132 AH Uner CJ Knupp AH Tatum Treatment with antibody reactive with the nephritogenic idiotype, IdLNF1, suppresses its production and leads to prolonged survival of NZB(SWR)F1 mice J Autoimmun 7 1994 27
133 JA Gross J Johnston S Mudri TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease Nature 404 6781 2000 995 999
134 T Dorner C Putterman B cells, BAFF/zTNF4, TACI, and systemic lupus erythematosus Arthritis Res 3 4 2001 197 199
135 BK Finck PS Linsley D Wofsy Treatment of murine lupus with CTLA4Ig Science 265 1994 1225
136 DI Daikh BK Finck PS Linsley Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/p39 costimulation pathways J Immunol 159 1997 3104
137 DI Daikh D Wofsy Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide J Immunol 166 2001 2913 2916
138 BH Hahn RR Singh WK Wong Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus Arthritis Rheum 44 2 2001 432 441
139 H Ishida T Muchamuel S Sakaguchi Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice J Exp Med 179 1994 305
140 BA Kiberd Interleukin-6 receptor blockage ameliorates murine lupus nephritis J Am Soc Nephrol 4 1993 58
141 B Wang Y Yamamoto NS El-Badri RA Good Effective treatment of autoimmune disease and progressive renal disease by mixed bone-marrow transplantation that establishes a stable mixed chimerism in BXSB recipient mice Proc Natl Acad Sci USA 96 6 1999 3012 3016
142 MJ Leandro JC Edwards G Cambridge An open study of B lymphocyte depletion in systemic lupus erythematosus Arthritis Rheum 46 10 2002 2673 2677
143 HM Lorenz Abetimus (La Jolla pharmaceuticals) Curr Opin Investig Drugs 3 2 2002 234 239
144 DJ Wallace Management of lupus erythematosus: recent insights Curr Opin Rheumatol 14 3 2002 212 219
145 RA Furie JM Cash ME Cronin Treatment of systemic lupus erythematosus with LJP 394 J Rheumatol 28 2 2001 257 266
145a D Alarcon-Segovia JA Tumlin RA Furie CJP 394 for the prevention of renal flare in patients with SLE: Results from a randomized, double-blind placebo controlled study Arthritis Rheum 48 2003 442 454
146 MC Genovese Z Uhrin DA Bloch Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis Arthritis Rheum 46 4 2002 1014 1018
147 J Sany Intravenous immunoglobulin therapy for rheumatic diseases [Review] Curr Opin Rheumatol 6 1994 305
148 E Ginzler HS Diamond M Weiner A multicenter study of outcome in systemic lupus erythematosus Arthritis Rheum 25 1982 605
149 EM Ginzler K Schorn Outcome and prognosis in systemic lupus erythematosus Rheum Dis Clin North Am 14 1988 67
150 MM Ward E Pyun S Studenski Long-term survival in systemic lupus erythematosus: Patient characteristics associated with poorer outcomes Arthritis Rheum 38 1995 274
151 S Jacobsen J Petersen S Ullman A multicentre study of 513 Danish patients with SLE. II. Disease mortality and clinical factors of prognostic value Clin Rheumatol 17 1998 478
152 HC Nossent TJG Swaak JHM Berden Systemic lupus erythematosus after renal transplantation: Patient and graft survival and disease activity Ann Intern Med 114 1991 183
153 JH Stone WJ Amend LA Criswell Outcome of renal transplantation in 97 cyclosporin-era patients with systemic lupus erythematosus and matched controls Arthritis Rheum 41 1998 438
154 JH Stone CL Millward JL Olson Frequency of recurrent lupus nephritis among 97 renal transplant patients during the cyclosporine era Arthritis Rheum 41 1998 678
155 MB Urowitz DD Gladman M Abu-Shakra Mortality studies in SLE: Results from a single center. III. Improved survival over 24 years J Rheumatol 24 1997 1061